NCT01077622 - A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 1, 2009

Primary Completion Date

April 1, 2011

Study Completion Date

April 1, 2011

Conditions

Leukaemia, Lymphocytic, Chronic

Interventions

DRUG

ofatumumab 100 mg, 1000 mg / vial

ofatumumab , 300mg followed by 7 weekly infusions 2000 mg, followed by 4 monthly infusions 2000mg

Trial Locations (7)

GSK Investigational Site, Aichi

GSK Investigational Site, Kanagawa

GSK Investigational Site, Nagasaki

GSK Investigational Site, Tokyo

GSK Investigational Site, Tokyo

GSK Investigational Site, Seoul

GSK Investigational Site, Seoul